Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study

Fig. 1

Study design. An IP of 56 weeks was followed by a 48-week DE period for patients in sustained SDAI remission (≤ 3.3 at both weeks 40 and 52 in the IP) and a 24-week post-treatment follow-up period (all patients). DE, de-escalation; EOW, every other week; IP, induction period; MTX, methotrexate; OL, open-label; QW, once-weekly; SC, subcutaneous; SDAI, Simplified Disease Activity Index; Wk, week. aSDAI ≤ 3.3 at both weeks 40 and 52: patients from treatment arm A were re-randomized into the DE period to one of three treatment arms (C: continuation, D: DE followed by withdrawal, or E: monotherapy) in a ratio of 1:1:1 at week 56. Patients in sustained SDAI remission from treatment arm B continued to receive this treatment in a blinded fashion. bDE completers. Previously presented at EULAR 2020 (poster SAT0104); copyright © the authors

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us